Tempest Therapeutics Inc - Asset Resilience Ratio
Tempest Therapeutics Inc (TPST) has an Asset Resilience Ratio of 1.38% as of March 2021. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2012–2018)
This chart shows how Tempest Therapeutics Inc's Asset Resilience Ratio has changed over time. Check TPST PP&E to net assets ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Tempest Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Tempest Therapeutics Inc (TPST) total market value.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $439.00K | 1.38% |
| Total Liquid Assets | $439.00K | 1.38% |
Asset Resilience Insights
- Limited Liquidity: Tempest Therapeutics Inc maintains only 1.38% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Tempest Therapeutics Inc Industry Peers by Asset Resilience Ratio
Compare Tempest Therapeutics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND |
Biotechnology | 0.00% |
|
ALTEOGEN Inc
KQ:196170 |
Biotechnology | 55.57% |
|
Apogee Therapeutics, Inc. Common Stock
NASDAQ:APGE |
Biotechnology | 47.01% |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX |
Biotechnology | 34.94% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Galapagos N.V.
AS:GLPG |
Biotechnology | 86.45% |
|
Blue Jet Healthcare Limited
NSE:BLUEJET |
Biotechnology | 13.81% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
Annual Asset Resilience Ratio for Tempest Therapeutics Inc (2012–2018)
The table below shows the annual Asset Resilience Ratio data for Tempest Therapeutics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2018-12-31 | 5.22% | $4.38 Million | $84.07 Million | -52.28pp |
| 2016-12-31 | 57.50% | $70.46 Million | $122.54 Million | -2.70pp |
| 2015-12-31 | 60.19% | $83.44 Million | $138.61 Million | -21.88pp |
| 2014-12-31 | 82.07% | $53.82 Million | $65.57 Million | +26.65pp |
| 2013-12-31 | 55.42% | $26.35 Million | $47.55 Million | +4.79pp |
| 2012-12-31 | 50.63% | $16.61 Million | $32.81 Million | -- |
About Tempest Therapeutics Inc
Tempest Therapeutics, Inc., a clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer. Its lead product candidates include Amezalpat, an oral small molecule selective antagonist of peroxisome proliferator-activated receptor alpha for the treatment of first-line unresectable or metastatic hepatocellular carcinoma that completed Phase 2 clinical trial; and TPST-14… Read more